Ad hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group ...
Summit Therapeutics SMMT is working to expand ivonescimab’s growth potential beyond non-small cell lung cancer (NSCLC), its ...
Colon cancer deaths are rising, and rates have risen for patients under 50. Colorectal cancer is the second most fatal in the U.S., and a projected 55,000 deaths are expected in 2026.
Colon cancer deaths are rising, and patients are getting younger. According to the National Cancer Institute, colorectal ...
Background The role of intrinsic tumour heterogeneity in driving organ-tropic metastasis in gastric cancer remains ...
Singapore scientists develop nanobody treatment targeting ascites to fight peritoneal cancer, with hopes for future clinical ...
Guardant Health’s oncology portfolio and Shield continue to help with its ongoing growth. It remains exposed to patent ...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that full abstracts from six studies of opamtistomig (LBL-024), its PD-L1/4-1BB bispecific ...
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup ...
Background:Early death from female breast cancer is influenced by disease biology and factors such as age, marginalization, ...
Guardant Health's Shield blood test achieved 99% real-world adherence in two rural clinics, far exceeding typical 28-71% ...
BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results